Management of cutaneous lupus erythematosus with low dose methotrexate: Indication for modulation of inflammatory mechanisms

Rheumatology International

Volumn 18, Issue 2, 1998, Pages 59-62

  Boehm, I B ^a   Boehm, G A ^b   Bauer, R ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cutaneous lupus erythematosus; Immunomodulatory activity; Low dose methotrexate

Indexed keywords

ANTIMALARIAL AGENT; AUTOANTIBODY; GLUCOCORTICOID; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0031660238     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960050058     Document Type: Article

References (22)

1. Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzales-Amaro R (1993) Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 20:731-733
2. Ferraccioli GF, de Vita S, Bartoli H (1995) Methotrexate benefits in patients with lupus with and without nephritis. J Rheumatol 22: 1442
3. Fink SD, Kremer JM (1995) Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate. J Rheumatol 22:967-969
4. Fox DA, McCune WJ (1994) Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 20:265-299
5. Hashimoto M, Nonaka S, Furuta E, Wada T, Suenaga Y, Yasuda M, Shingu M, Nobunaga M (1994) Methotrexate for steroid-resistant systemic lupus erythematosus. Clin Rheumatol 13:280-283
6. Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG (1988) The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 31:612-615
7. Walz LeBlanc BA, Dagenais P, Urowitz MB, Gladman DD (1994) Methotrexate in systemic lupus erythematosus. J Rheumatol 21:836-838
8. Wilson K, Abeles M (1994) A 2-year, open-ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 21:1674-1677
9. Böhm I, Uerlich M, Bauer R (1997) Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 194:307-308
10. Bottomley WW, Goodfield MJ (1995) Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol 133:655-656
11. Goldstein E, Carey W (1994) Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol 130:938-939
12. Boehm I, Bauer R (1997) Low-dose methotrexate: an immunomodifying therapeutic strategy for dermatologic diseases. In: Burg, Dummer (eds) Strategies for immunointerventions in dermatology. Springer, Berlin Heidelberg New York, pp 59-70
13. Chang DM, Baptiste P, Schur PH (1990) The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 inhibitor production by human monocytes. J Rheumatol 17:1148-1157
14. Martinez-Osuna P, Zwolinska JB, Sikes DH, Cory JG, Silveira LH, Jara LJ, Espinoza LR (1993) Lack of immunosuppressive effect of low-dose oral methotrexate on lymphocytes in rheumatoid arthritis. Clin Exp Rheumatol 11:249-253
15. Segal R, Mozes E, Yaron M, Tartakovsky B (1989) The effect of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 32:370-377
16. Brody M, Böhm I, Bauer R (1993) Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1b to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 31:667-674
17. Sander DN, Wong D, Laskin C (1993) Epidermal cytokines in murine lupus. J Invest Dermatol 100:42S-46S
18. Hsieh SC, Tsai CY, Sun KH, Tsai YY, Tsai ST, Han SH, Yu HS, Yu CL (1995) Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Br J Rheumatol 43:107-112
19. O'Meara AMW, Brazil J, Reen DJ (1985) The effect of methotrexate on in vitro immunoglobulin production. J Immunopharmacol 7:235-245
20. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147:117-123
21. Tanaka Y, Saito K, Suzuki H, Eto S, Yamashita U (1989) Inhibitory effect of anticlass II antibody on the spontaneous activation of B cells in patients with systemic lupus erythematosus. Analysis with interleukin 1 production and interleukin 1 receptor expression. J Immunol 143:1584-1590
22. Roenigk HH Jr, Auerbach R, Maihach HI, Weinstein GD (1988) Methotrexate in psoriasis: revisted guidelines. J Am Acad Dermatol 19:145-156